TRAF3IP2 and soft tissue sarcoma: Recently, CSPG4-specific chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CSPG4-CAR.CIKs) effectively targeted multiple soft tissue sarcomas (STS) histotypes in vitro and in vivo [26].